CN111868089B - B7-h4抗体给药方案 - Google Patents

B7-h4抗体给药方案

Info

Publication number
CN111868089B
CN111868089B CN201980019155.0A CN201980019155A CN111868089B CN 111868089 B CN111868089 B CN 111868089B CN 201980019155 A CN201980019155 A CN 201980019155A CN 111868089 B CN111868089 B CN 111868089B
Authority
CN
China
Prior art keywords
antibody
antigen
ser
binding fragment
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980019155.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111868089A (zh
Inventor
S·P·艾那姆达尔
H·L·科林斯
张翔
向红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of CN111868089A publication Critical patent/CN111868089A/zh
Application granted granted Critical
Publication of CN111868089B publication Critical patent/CN111868089B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980019155.0A 2018-02-21 2019-02-21 B7-h4抗体给药方案 Active CN111868089B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US62/633,527 2018-02-21
US201962802100P 2019-02-06 2019-02-06
US62/802,100 2019-02-06
PCT/US2019/018963 WO2019165075A1 (en) 2018-02-21 2019-02-21 B7-h4 antibody dosing regimens

Publications (2)

Publication Number Publication Date
CN111868089A CN111868089A (zh) 2020-10-30
CN111868089B true CN111868089B (zh) 2025-08-22

Family

ID=65686103

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980019155.0A Active CN111868089B (zh) 2018-02-21 2019-02-21 B7-h4抗体给药方案

Country Status (13)

Country Link
US (3) US20210070862A1 (https=)
EP (1) EP3755719A1 (https=)
JP (2) JP7258038B6 (https=)
KR (1) KR102863169B1 (https=)
CN (1) CN111868089B (https=)
AU (1) AU2019226009B2 (https=)
BR (1) BR112020016990A2 (https=)
CA (1) CA3091161A1 (https=)
IL (1) IL276623A (https=)
MA (1) MA51902A (https=)
MX (1) MX2020008730A (https=)
SG (1) SG11202007820QA (https=)
WO (1) WO2019165075A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672990A1 (en) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
JP2021514379A (ja) * 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
WO2020081497A1 (en) * 2018-10-15 2020-04-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
JP2024501894A (ja) 2021-01-04 2024-01-16 メルサナ セラピューティクス インコーポレイテッド Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094352A (zh) * 2017-08-25 2020-05-01 戊瑞治疗有限公司 B7-h4抗体及其使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
CN103540600B (zh) 2003-01-22 2017-12-01 罗氏格黎卡特股份公司 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
JP2008539753A (ja) 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
JP6120848B2 (ja) * 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
AU2013361275B2 (en) * 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
JP2021514379A (ja) * 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094352A (zh) * 2017-08-25 2020-05-01 戊瑞治疗有限公司 B7-h4抗体及其使用方法

Also Published As

Publication number Publication date
CN111868089A (zh) 2020-10-30
JP2023089063A (ja) 2023-06-27
MA51902A (fr) 2021-05-26
AU2019226009B2 (en) 2025-11-20
AU2019226009A1 (en) 2020-09-03
SG11202007820QA (en) 2020-09-29
WO2019165075A1 (en) 2019-08-29
US20210070862A1 (en) 2021-03-11
EP3755719A1 (en) 2020-12-30
JP7258038B2 (ja) 2023-04-14
MX2020008730A (es) 2020-12-07
US20230287123A1 (en) 2023-09-14
KR20200123169A (ko) 2020-10-28
JP7258038B6 (ja) 2023-04-25
US20240317864A1 (en) 2024-09-26
BR112020016990A2 (pt) 2021-02-23
KR102863169B1 (ko) 2025-09-22
CA3091161A1 (en) 2019-08-29
IL276623A (en) 2020-09-30
JP2021513997A (ja) 2021-06-03

Similar Documents

Publication Publication Date Title
KR102761792B1 (ko) B7-h4 항체 및 그의 사용 방법
KR101993921B1 (ko) Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
CN113166242B (zh) 用于癌症的组合疗法
CN111868089B (zh) B7-h4抗体给药方案
KR20200123170A (ko) B7-h4 항체 제형
EA031069B1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
KR20150013321A (ko) Ｃｄ33 항체 및 암을 치료하기 위한 이의 용도
TW201008579A (en) Anti-Fn14 antibodies and uses thereof
KR102478986B1 (ko) 암 치료용 항-ck8 항체
CN115244084A (zh) 抗gitr抗体及其用途
CN116887859A (zh) Ccr6抗体
CN114845738A (zh) 使用位点特异性her2抗体-药物缀合物的治疗
HK40036127B (zh) B7-h4抗体给药方案
HK40036127A (en) B7-h4 antibody dosing regimens
HK40057716A (en) Combination therapy for cancer
HK40057716B (zh) 用於癌症的组合疗法
HK40036133A (zh) B7-h4抗体制剂
EA043376B1 (ru) Составы антитела b7-h4
HK40027698A (en) B7-h4 antibodies and methods of use thereof
EA048025B1 (ru) Комбинированная терапия онкологического заболевания
HK40068969A (en) Treatment with site specific her2 antibody-drug conjugates
TW201241181A (en) Humanized antibodies to LIV-1 and use of same to treat cancer
HK40027698B (zh) B7-h4抗体及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036127

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment